1X8.SG - Creso Pharma Ltd
Stuttgart - Stuttgart Delayed Price. Currency in EUR
At close: 08:25AM CEST
Stock chart is not supported by your current browser
| Previous Close | 0.0050 |
| Open | 0.0050 |
| Bid | 0.0050 x 0 |
| Ask | 0.0065 x 0 |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0050 - 0.0354 |
| Volume | |
| Avg. Volume | 19,827 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Creso Pharma Insiders Lose Out As Stock Sinks To AU$0.009 \
Insiders who acquired AU$300k worth of Creso Pharma Limited's ( ASX:CPH ) stock at an average price of AU$0.04 in the...
- Simply Wall St.
Creso Pharma Full Year 2022 Earnings: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)
Creso Pharma ( ASX:CPH ) Full Year 2022 Results Key Financial Results Revenue: AU$9.03m (up 45% from FY 2021). Net...
CNW GroupHalucenex Life Sciences Inc. targets Australian market following landmark TGA decision
Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. ('Halucenex'), is exploring opportunities to register its synthetic psilocybin formulation for the Australian market following recent regulatory changes.